AR/PARP Dual‐Targeting Bioactive Photosensitizer for Photo‐Immunotherapy of Prostate Cancer
Advanced Materials · 2026
DOI: 10.1002/adma.74964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Zhifang Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Precision Research Center For Refractory Diseases in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. Chi…. Hauptthemen laut MEDLINE: Immunotherapy, Photosensitizing Agents, Poly(ADP-ribose) Polymerases, Prostatic Neoplasms. Die Arbeit nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Prostate cancer poses a severe threat to men's health worldwide, and conventional therapeutic modalities are associated with various limitations. Photodynamic therapy (PDT) offers distinctive advantages such as minimal invasiveness, mild side effects and repeatable treatment. However, the therapeutic efficacy of PDT is limited by two critical factors: the single functional property of traditional photosensitizers and the pathological tumor microenvironment. Accordingly, molecular targeting photosensitizers have been developed to address these drawbacks. Notably, long‐term administration of single‐target agents entails a high risk of drug resistance. Accordingly, based on two key targets closely implicated in the DNA repair pathways of prostate cancer cells, the androgen receptor (AR), and poly(ADP‐ribose) polymerase (PARP), we proposed an AR/PARP dual‐targeting photosensitizer strategy and synthesized a quinoxalinone‐based photosensitizer QTEO , which can simultaneously target AR and PARP and exert a synergistic effect with photodynamic activity to induce DNA damage in cancer cells. The resulting damaged DNA fragments can further activate the innate immune pathways of the organism through a coordinated cascade of reactions. This promising strategy concurrently overcomes the limited functionality of conventional photosensitizers, the potential drug resistance induced by single‐target agents, and the complex pharmacokinetic issues associated with multidrug combination therapy, ultimately enabling molecular‐targeting photo‐immunotherapy for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Research Center For Refractory Diseases in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
- Department of Pharmacy, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
- Yuebei People's Hospital Affiliated to Shantou University Medical College, Shaoguan, Guangdong, China.
- Department of Urology, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Frontiers Science Center For Transformative Molecules (FSCTM), School of Chemistry and Chemical Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.
- SJTU Asia-Pacific Graduate Institute (SJTU-APGI), Singapore, Singapore.
ORCID-Profile: Qiyu Chen, Tao Shen, Leilei Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Shenzhen Science and Technology Program
- Key Discipline of Shanghai Municipal Health Commission
- China Postdoctoral Science Foundation
- Prime Minister's Office, Singapore
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Yang, Z., Wang, M., Chen, Q., Zhang, K., Zhou, M., Li, H., Yang, J., Zhu, Y., Shen, T., Li, L., & Shi, L. (2026). AR/PARP Dual‐Targeting Bioactive Photosensitizer for Photo‐Immunotherapy of Prostate Cancer. Advanced Materials. https://doi.org/10.1002/adma.74964
Vancouver
Yang Z, Wang M, Chen Q, Zhang K, Zhou M, Li H, et al. AR/PARP Dual‐Targeting Bioactive Photosensitizer for Photo‐Immunotherapy of Prostate Cancer. Advanced Materials. 2026. doi:10.1002/adma.74964
BibTeX
@article{Yang2026,
author = {Yang, Zhifang and Wang, Minjia and Chen, Qiyu and Zhang, Kai and Zhou, Minqi and Li, Hongyu and Yang, Jiapei and Zhu, Yingjian and Shen, Tao and Li, Ling and Shi, Leilei},
title = {AR/PARP Dual‐Targeting Bioactive Photosensitizer for Photo‐Immunotherapy of Prostate Cancer},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.74964}
}
EUVIMED